Stocklytics Platform
Asset logo for symbol CSTL
Castle Biosciences
CSTL65
$27.58arrow_drop_down0.68%-$0.18
Asset logo for symbol CSTL
CSTL65

$27.58

arrow_drop_down0.68%
Key Stats
Open$27.77
Prev. Close$27.83
EPS0.21
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
LOWHIGH
Day Range27.01
28.36
52 Week Range12.07
36.00
Ratios
EPS0.21
Fundamentals
Payout Ratio-
Industry average yield3.08%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

CSTL-
US Healthcare Sector-
US Market-
warning

CSTL / Market

CSTL lose to the US Market which returned -0.18% over the last twenty four hours.
warning

CSTL / Healthcare Sector

CSTL lose to the US Healthcare sector which returned 1.27% over the last twenty four hours.

Castle Biosciences (CSTL) Statistics

Castle Biosciences Inc (CSTL) is a biotechnology company that specializes in providing diagnostic and prognostic solutions for patients with rare and difficult-to-diagnose cancers. The company develops and commercializes molecular and genomic tests that help physicians make more accurate treatment decisions. Castle Biosciences has a strong focus on improving patient outcomes and reducing healthcare costs by enabling more personalized and targeted therapies. CSTL stock has been performing well in recent years, reflecting the company's strong fundamentals and growth potential.
When it comes to valuation metrics, Castle Biosciences Inc (CSTL) stands out from its peers. The company's price-to-sales ratio, a commonly used valuation ratio for biotech companies, is significantly lower than the industry average. This indicates that CSTL stock is undervalued relative to its revenue per share, making it an attractive investment opportunity. Another important metric to consider is the enterprise to EBITDA ratio, which measures a company's profitability. Castle Biosciences Inc has a favorable enterprise to EBITDA ratio compared to its sector, indicating that it is generating strong profits relative to its enterprise value.
add Castle Biosciences  to watchlist

Keep an eye on Castle Biosciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Castle Biosciences (CSTL) stock's performance compared to its sector and the market over the past year?

Over the past year, Castle Biosciences (CSTL) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 20.78%, Castle Biosciences has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 44.09%, it has fallen short of the market average. This comparison highlights Castle Biosciences 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Castle Biosciences (CSTL) stock?

The PE (Price to Earnings) ratio of Castle Biosciences (CSTL) is currently 131.36. This metric is used to evaluate the valuation of a company's stock, comparing its current share price relative to its per-share earnings.
help

What is the EPS of Castle Biosciences (CSTL) stock?

The Earnings Per Share (EPS) for Castle Biosciences (CSTL), calculated on a diluted basis, is $0.21. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Castle Biosciences (CSTL) stock?

The operating margin for Castle Biosciences (CSTL) is 5.92%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Castle Biosciences (CSTL) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Castle Biosciences (CSTL) is $25.08M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Castle Biosciences (CSTL) have?

Castle Biosciences (CSTL) has a total debt of $26.74M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$68.22M.

Take Your Investments to a Whole New Level